Kestra Medical officer proposes $312K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) lists Brian Webster, an officer and director, for a proposed sale of 15,000 common shares, with an approximate sale date of June 15, 2026 and aggregate market value of $312,142.94. The shares were acquired January 21, 2026 through a restricted share issuance under the issuer’s equity compensation plan. The notice lists September 29, 2025 as the Rule 10b5-1 plan adoption date. Four prior sales of 15,000 shares each are listed for February 17, March 17, April 15 and May 15, 2026.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Aggregate Market Value financial
equity compensation plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.